The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant chemotherapy with interval debulking surgery (NACT-IDS) reduces unadjusted 30-day perioperative mortality versus primary debulking surgery (PDS) in women aged ≥70 with FIGO IIIC/IV epithelial ovarian cancer (RR=0.20).
- Why it matters: Older women with advanced epithelial ovarian cancer face high surgical morbidity and mortality, and evidence syntheses focused on geriatric decision-making remain limited.
- What they did: A PRISMA 2020 systematic review and meta-analysis (PROSPERO CRD420261461644) pooled 11 retrospective cohort studies (>16,500 patients), comparing NACT-IDS vs PDS using random-effects models, with ROBINS-I, TSA, and GRADE.
- The result: NACT-IDS shortened hospital stay (MD=-3.12 days, p=0.0044), increased complete macroscopic resection (R0=0 cm) by 74% (RR=1.74, p=0.047), and showed a lower severe complication trend (Clavien-Dindo ≥3; RR=0.38). Unadjusted survival was linked to higher death hazard (HR=1.13) likely due to selection bias, with overall evidence rated Very Low.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.